|Status: In progress|
Treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in children.
Patients started on anti-TNF would have been started after oral therapy, for example, 5-ASA or azathioprine and/or be considered with severe disease and started on anti-TNF first line.
|Medicine name||vedolizumab (Entyvio®)|
|Company||Takeda UK Ltd|
|BNF chapter||Gastro-intestinal system|
|Submission type||One Wales|
|Date of issue||TBA|